Our recent observation that HsRAD52-S346X protects against breast cancer in carriers of pathogenic BRCA2 mutations [30] suggests the possibility that a similar loss of HsRAD52-dependent HRR in human cells may contribute to the synthetic lethality that underlies this protection. Here, BRCA2 is linked to breast carcinoma.